Find disease awareness content and relevant supporting materials
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective.
Panobinostat is an oral pan-histone deacetylase inhibitor developed by Novartis. Panobinostat acts via epigenetic modification and inhibition of the aggresome pathway.
Phase I/II dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in Hodgkin�s Disease, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia
Phase I part:� - To assess the MTD and the dose-limiting toxicities (DLTs).� Phase II part: - To assess the objective response rate...
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
This update covers recommendations for glioblastoma; anaplastic astrocytoma, oligoastrocytoma and oligodendroglioma; and diffuse glioma. The recommendations cover clinically relevant problems in: diagnosis and pathology...
Brain invasion in meningiomas-clinical considerations and impact of neuropathological evaluation: a systematic review.
With the release of the 2016 edition of the WHO Classification of Central Nervous System Tumors, brain invasion in meningiomas has been added as a stand-alone criterion for atypia and can therefore impact grading and indirectly adjuvant therapy.
The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.
The therapeutic armamentarium for multiple myeloma has recently benefited from the addition of several new agents (including second-generation proteasome inhibitors, monoclonal antibodies and histone deacetylase inhibitors).